Log In
Print this Print this

HyNap nilotinib

  Manage Alerts
Collapse Summary General Information
Company XSpray Microparticles AB
DescriptionFormulation of nilotinib, a BCR-ABL tyrosine kinase inhibitor, using XSpray's HyNap hybrid nanoparticle technology
Molecular Target BCR-ABL tyrosine kinase (BCR-ABL)
Mechanism of ActionBCR-ABL tyrosine kinase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today